Market Movers (8-K)
OQB
AccuStem Sciences Inc.'s MSC test, a non-invasive blood-based assay for lung cancer risk, has advanced to the review queue for Medicare reimbursement with Novitas Solutions.
OQB
AccuStem Sciences Inc. has appointed Mercurius & Associates LLP as its new independent registered public accounting firm, replacing the previous auditor.
OQB
AccuStem Sciences Inc. has appointed Mercurius LLP as its new independent registered public accounting firm, effective June 17, 2024.
OQB
AccuStem Sciences Inc. has announced that its independent auditor, Mazars USA LLP, will resign effective upon the filing of the company's Form 10-Q for the quarter ended March 31, 2024.
Worse than expected
Quarterly Earnings (10-Q)
See all →OQB
AccuStem Sciences reported increased net losses in Q3 2025, driven by higher R&D and administrative costs, while actively seeking new equity financing to address critical liquidity concerns.
Worse than expected
Delay expected
Capital raise
OQB
AccuStem Sciences, Inc. reported increased losses and a significant going concern risk, necessitating immediate additional financing to continue operations.
Worse than expected
Capital raise
Delay expected
OQB
AccuStem Sciences reports a net loss for Q1 2025 while advancing the commercialization of its MSC lung test and StemPrintER breast cancer test.
Capital raise
Worse than expected
OQB
AccuStem Sciences reports a net loss of $1.13 million for the nine months ended September 30, 2024, and acknowledges the need for additional financing to continue operations.
Worse than expected
Capital raise
OQB
AccuStem Sciences reported a net loss for the second quarter of 2024 and highlighted ongoing efforts to commercialize its StemPrintER test while facing significant funding challenges.
Worse than expected
Capital raise
OQB
AccuStem Sciences reported a net loss of $526,602 for the first quarter of 2024 and highlighted the need for additional financing to continue operations.
Worse than expected
Capital raise
Annual Reports (10-K)
OQB
AccuStem Sciences, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing continued net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OQB
AccuStem Sciences outlines its plans to commercialize its MSC and StemPrintER diagnostic tests while reporting a net loss for the year ended December 31, 2024.
Capital raise
Worse than expected
OQB
AccuStem Sciences Inc.'s 2023 annual report highlights the company's focus on commercializing its StemPrintER test while navigating financial losses and the need for additional funding.
Worse than expected
Capital raise
Insider Trading (Form 4)
OQB
Gabriele M. Cerrone, a Director and 10% owner of Accustem Sciences Inc., purchased additional common stock through a pre-arranged trading plan.
OQB
Gabriele M. Cerrone, a Director and 10% Owner of Accustem Sciences Inc., has increased his indirect beneficial ownership of common stock through two recent purchases totaling 37,196 shares.
Better than expected
OQB
Form 4: Accustem Sciences Inc. Director Gabriele M. Cerrone Increases Stake Through Open Market Purchases
Director Gabriele M. Cerrone reports acquiring additional shares of Accustem Sciences Inc. through open market purchases, increasing his indirect holdings.
OQB
Gabriele M. Cerrone, a director and 10% owner of Accustem Sciences Inc., has increased his indirect holdings of common stock through a series of purchases via Panetta Partners Limited.
OQB
Accustem Sciences director Gabriele M. Cerrone acquired 100,000 shares of common stock at $0.381 per share on December 31, 2024.